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The effect of nonmuscle actin ADP-ribosylated by botulinum C2 toxin on the polymerization f nonmuscle actin was 
investigated in order to clarify whether nonmuscle actin is converted into a capping protein by ADP-ribosylation. ADP- 
ribosylated actin was found to decrease the rate of polymerization factin filaments which are free at both ends. ADP- 
ribosylated actin turned out to have no effect on the rate or extent of polymerization at the pointed ends of actin filaments 
the barbed ends of which were capped by gelsolin. The monomer concentration reached at the final stage of polymeriza- 
tion was similar to the critical concentration f the pointed ends of actin filaments. The results uggest that nonmuscle 
actin ADP-ribosylated by botulinum C2 toxin acts as a capping protein which binds to the barbed ends to inhibit 
polymerization. 
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1. INTRODUCTION 
Botulinum C2 toxin is one of eight known toxins 
produced by different types of Clostridium 
botulinum [1]. Among these toxins, botulinum C2 
toxin is unique in its structural and functional 
properties [2]. Botulinum C2 toxin is binary in 
structure and consists of two components [3]. Ap- 
parently, component II is involved in binding of 
the toxin to the eukaryotic ell membrane [4], 
while component I possesses ADP-ribosyltransfer- 
ase activity [5] and modifies actin [6,7]. The 
substrate of botulinum C2 toxin is monomeric 
nonmuscle G-actin but not polymerized F-actin. In 
contrast to botulinum neurotoxins A-G,  
botulinum C2 toxin is not neurotoxic but induces 
cytopathic effects [8-10]. The toxin destroys the 
microfilament etwork and causes rounding up of 
intact cells [9]. These effects were correlated with 
toxin-induced ADP-ribosylation of actin. Recently 
it has been shown that ADP-ribosylated skeletal 
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muscle actin which was modified by Perfringens 
iota toxin, caps actin filaments [11]. Skeletal mus- 
cle actin, which is highly homologous to nonmusle 
actin [12], is a poor substrate of botulinum C2 
toxin [6]. In order to gain further insight into the 
mechanism of the cytopathic effects of botulinum 
C2 toxin on nonmuscle cells and to determine 
whether ADP-ribosylated nonmuscle actin behaves 
also as a capping protein, we have investigated the 
effect of ADP-ribosylation of nonmuscle actin on 
the polymerization of liver actin. 
2. MATERIALS AND METHODS 
2.1. Preparation of proteins 
Component I of botulinum C2 toxin was purified from 
culture medium of C. botulinum type C strain 9213 essentially 
as described [3]. Actin was prepared from pig liver according to 
[13] with the following modification. Before chromatography 
the protein was dialyzed vs buffer A (0.5 mM ATP, 0.2 mM 
CaCI2, 5 mM triethanolamine-HCl, pH 7.5, and 3 mM NAN3). 
The protein was then applied to a Sephacryl S-200 column 
(2.5 x 90 cm) equilibrated with buffer A. The concentration f 
actin was determined photometrically at 290 nm using an ab- 
sorption coefficient of 24900 M-t .cm -~ [14]. Fluorescently 
labeled actin was produced by modification of actin with 
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7-chloro-4-nitro-2-oxa-l,3-benzdiazole [15]. ADP-ribosylated 
actin was prepared by incubation of 20/zM monomeric actin in 
a medium containing 4/~g component I of botulinum C2 toxin, 
0.1 mM NAD, 0.45 mM ATP, 0.18 mM CaC12, 0.02mM 
MgC12, 9.5 mM triethanolamine-HCl (pH 7.5), 1 mM 
dithiothreitol and 2.7 mM NaN3 for 1 h at 37°C in a total 
volume of 1 ml. The amount of ADP-ribosylated actin was 
determined asdescribed [16]. About 50070 of the given actin was 
ADP-ribosylated. Gelsolin-actin complex was prepared from 
human platelet concentrate. Platelets were purified according to 
[17]. Gelsolin-actin complex was isolated as in [18] with some 
modifications [19]. The concentration f gelsolin-actin complex 
was determined according to [19]. 
2.2. Experimental design 
Actin polymerization was followed by a 2.2-2.5-fold greater 
fluorescence intensity of polymeric actin vs that of monomeric 
actin [ 15]. 5070 of fluorescently labeled actin was copolymerized 
with unmodified actin. The excitation wavelength was 480 nm, 
and the fluorescence intensity was measured at 540 nm. 
Changes in fluorescence intensities were evaluated in terms of 
concentrations of monomeric or polymeric actin. Fluorescence 
intensities of monomeric or polymeric actin were calibrated by 
measuring those of a dilution series of monomeric or polymeric 
actin. Fluorescence samples were prepared by mixing buffer A, 
a salt solution (10 mM MgCI2, 500 mM KC1) and various pro- 
tein solutions. A 4/LM polymeric actin solution was obtained by 
addition of 100 mM KCI and 2 mM MgC12 to monomeric actin. 
Actin filaments capped at the barbed ends were formed by 
polymerizing 4/zM actin onto 50 nM gelsolin-actin complex in 
the presence of 100 mM KCI and 2 mM MgC12. The solutions 
were mixed in a ratio such that the final composition of the 
samples was 100 mM KCI, 2 mM MgC12, 0.18 mM CaCI2, 
0.45 mM ATP, 4.5 mM triethanolamine-HCl (pH 7.5), 
2.7 mM NaN3 and the desired concentrations of ADP- 
ribosylated actin, monomeric actin, polymeric actin or gelsolin- 
capped actin filaments. In every case, the salt solution and buf- 
fer A were first combined and then ADP-ribosylated actin, 
monomeric actin and finally polymeric actin or gelsolin-capped 
filaments were added. All experiments were carried out at 37°C. 
3. RESULTS 
3.1. Effect of ADP-ribosylated actin on 
polymerization of barbed and pointed ends of 
actin filaments 
1/zM monomeric actin was polymerized onto 
0.5/@M polymeric actin in the presence of various 
concentrations of ADP-ribosylated actin. The time 
course of polymerization is depicted in fig.1. The 
rate of polymerization a d the final concentration 
of polymerized actin were decreased by ADP- 
ribosylated actin. In order to test the specificity of 
the effect of ADP-ribosylated actin for the two 
ends of actin filaments, actin polymerization to 
the pointed ends was investigated in the presence 
of ADP-ribosylated actin. Actin filaments capped 
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Fig.1. Nucleated polymerization of actin in the presence of 
ADP-ribosylated actin, cf, concentration f polymerized actin. 
1/zM monomeric actin was added to 0.5/zM polymeric actin in 
the presence of the following concentrations of ADP- 
ribosylated actin: (o) 0/zM, (zx) 0.2/zM, (+) 0.8/zM, (n) 
2.0/tM. 
at the barbed ends were prepared by combining 
gelsolin-actin complex with monomeric actin. 
Monomeric actin was polymerized onto the 
pointed ends of these gelsolin-capped filaments in 
the presence of various concentrations of ADP- 
ribosylated actin. The results depicted in fig.2 
demonstrate hat even 1/~M ADP-ribosylated ac- 
tin neither etarded polymerization at the pointed 
ends nor decreased the final concentration of 
polymerized actin. Thus, ADP-ribosylated actin 
did not affect the pointed ends. Retardation of 
nucleated actin polymerization a d the decrease in
final polymeric actin concentration depicted in 
fig. 1 must be attributed to specific inhibition by 
ADP-ribosylated actin of the actin assembly at the 
barbed ends. The results suggest that ADP- 
ribosylated actin caps the barbed ends of actin 
filaments to inhibit monomer binding at these 
ends. 
3.2. Effect of ADP-ribosylated actin on 
monomer concentration of actin 
Capping activity of ADP-ribosylated actin was 
investigated by its effect on the concentration of
monomers which coexist with filaments [20]. 
Under the given experimental conditions (100 mM 
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Fig.2. Polymerization onto gelsolin-capped actin filaments in 
the presence of ADP-ribosylated actin. ,acf, change in 
concentration f polymerized actin. Gelsolin-capped filaments, 
which were prepared by combining 0.1/JM gelsolin-actin 
complex with 2/~M monomeric actin, were added to 2/~M 
monomeric actin in the presence of the following 
concentrations of ADP-ribosylated actin: (e) 0/zM, (A) 1/zM. 
KCI, 2 mM MgCI2, pH 7.5, 37°C) actin filaments 
treadmill, i.e. the barbed ends polymerize while the 
pointed ends depolymerize, leading to a flux of 
subunits along actin filaments from the barbed to 
the pointed ends [14]. Thus, capping proteins 
which bind to the barbed ends and inhibit 
polymerization at these ends are expected to in- 
crease the monomer concentration, since monomer 
consumption at the barbed ends is inhibited, 
however, monomers are still produced by 
depolymerizing pointed ends [19,20]. In fig.3 a 
plot of the monomer concentration reached at the 
final stage of nucleated polymerization vsconcen- 
tration of ADP-ribosylated actin is presented. 
Maximally about 1/~M actin was in the monomeric 
state. Fig.2 shows that on addition of 2/~M 
monomeric actin to gelsolin-capped filaments 
1.1-1.2/~M actin polymerizes onto the pointed 
ends of gelsolin-capped filaments while 0.8 or 
0.9/~M actin remains in the monomeric state. 
Thus, the critical monomer concentration of the 
pointed ends of gelsolin-capped filaments is about 
0.85/~M. This value corresponds approximately to 
the maximal monomer concentration reached by 
addition of ADP-ribosylated actin. Furthermore, 
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Fig.3. Plot of the final steady-state monomer concentration c~ 
vs the concentration f ADP-ribosylated actin at. The monomer 
concentration was determined following nucleated polymeriza- 
tion of actin (0.5/~M polymeric actin plus 1.0/~M monomeric 
actin). ( ) Critical concentration of the pointed end. 
the plot in fig.3 displays a hyperbolic shape which 
is typical for capping proteins [20]. 
4. DISCUSSION 
In this paper, we have demonstrated that non- 
muscle liver actin which is ADP-ribosylated by 
botulinum C2 toxin exhibits capping activity 
similar to that of skeletal muscle actin ADP- 
ribosylated by Perfringens iota toxin. Thus, the 
present data suggest a likely explanation for the 
cytopathic effects to be, for example, the 
disorganization of the microfilament network 
observed after treatment of intact cells with 
botulinum C2 toxin [9]. ADP-ribosylation by 
botulinum C2 toxin converts actin into a capping 
protein which blocks polymerization at the barbed 
ends of actin filaments but does not affect pointed 
ends. During the course of actin treadmilling, 
capped actin filaments depolymerize atthe pointed 
end. The released G-actin, which is a substrate of 
the toxin, accumulates since ADP-ribosylated ac- 
tin is not able to polymerize. Finally, all these 
events cause destruction of the microfilament 
network. 
In addition to botulinum C2 toxin, other 
microbial toxins such as Perfringens iota toxin 
[16], C. spiroforme toxin [21] and an ADP- 
ribosyltransferase produced by C. difficile [22] 
belong to the novel class of actin-modifying ADP- 
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r ibosyl t ransferases.  Recent reports indicate that  
these agents most  l ikely mod i fy  act in at an iden- 
t ical amino  acid [21-24] .  Thus ,  it is feasible that  
all these ADP- r ibosy la t ing  toxins affect act in- 
dependent  cel lular funct ions  by capping of  act in 
f i laments  and  remova l  of  act in f rom the 
po lymer izab le  pool .  
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